August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
2 citations
,
January 2017 in “Düşünen Adam” Agomelatine might help stop hair loss caused by valproate.
3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
7 citations
,
March 2012 in “European Journal of Pediatrics” A boy with a rare skin condition and kidney disease improved with cyclosporine after steroids failed, suggesting a new treatment approach.
October 2024 in “Media Farmasi” Combining soursop leaf extract with doxorubicin may improve breast cancer treatment and reduce side effects.
August 2024 in “Siberian Journal of Life Sciences and Agriculture” Melatonin and lyotritone improve hair growth and quality in white rats.
32 citations
,
March 2009 in “AAPS PharmSciTech”
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
36 citations
,
February 2016 in “British journal of pharmacology” Sirtuin 1 could be a potential drug target for treating hypertrophic scars.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
April 2010 in “Nature Reviews Urology” 46 citations
,
April 1982 in “Journal of the American Academy of Dermatology” Isotretinoin shrinks sebaceous glands without affecting hair or skin color, unlike etretinate.
January 2015 in “International Journal of Nanomedicine” Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
September 2021 in “Revista Interdisciplinar em Saúde” Oral isotretinoína effectively stabilizes frontal fibrosing alopecia.
February 2025 in “Biomolecules” RORA boosts autophagy in hair follicle stem cells, potentially aiding hair growth.
September 2019 in “Journal of Investigative Dermatology” Sandalore®, a synthetic scent, reduced hair loss and improved hair growth in women with telogen effluvium.
31 citations
,
January 1981 in “Pharmacology & Therapeutics” Oral retinoids are effective for treating severe skin disorders but have reversible side effects and risks for pregnant women.
January 2018 in “International journal for pharmaceutical research scholars” Meniran extract hair tonic may stimulate hair growth in rats, with the version containing 1% menthol being more effective.
13 citations
,
November 2005 in “Epilepsia” Deoxycorticosterone and its metabolites help prevent seizures by interacting with specific receptors.
August 2024 in “Journal of Dermatology & Cosmetology” Acitretin effectively prevented skin cancer in a patient with late-onset Rothmund-Thomson syndrome.
1 citations
,
June 2016 in “Annals of the rheumatic diseases” Retinoids may help treat lupus nephritis and reduce steroid use.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.